Uncategorized
Bevacizumab may enhance deep sclerectomy IOP-lowering outcomes
Subconjunctival injection of bevacizumab may enhance IOP-lowering effects of primary deep sclerectomy without the bleb complications that can accompany surgery with mitomycin C, according to a study.In the retrospective, comparative case-control study, MMC was applied before scleral flap dissection in 32 eyes, and Avastin (bevacizumab, Genentech) was injected at the end of surgery in 43 eyes.